MKI67 and neoplasm: Although a single dose of engineered TBSV NPs was unable to significantly change cyclin D1 expression levels, the reduced content in Ki67 resulting from the analysis of early stages of MB development suggests that TBSV-based DOX delivery platform inhibits tumor cell proliferation as effectively as a five-fold higher dose of free-DOX.